Yongli Du

478 total citations
29 papers, 394 citations indexed

About

Yongli Du is a scholar working on Molecular Biology, Genetics and Immunology. According to data from OpenAlex, Yongli Du has authored 29 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 10 papers in Genetics and 7 papers in Immunology. Recurrent topics in Yongli Du's work include Estrogen and related hormone effects (10 papers), Bioactive Compounds and Antitumor Agents (6 papers) and Galectins and Cancer Biology (6 papers). Yongli Du is often cited by papers focused on Estrogen and related hormone effects (10 papers), Bioactive Compounds and Antitumor Agents (6 papers) and Galectins and Cancer Biology (6 papers). Yongli Du collaborates with scholars based in China and United States. Yongli Du's co-authors include Qunyi Li, Jingkang Shen, Liudi Zhang, Xiaojin Shi, Peihong Liu, John J. Jeffrey, Weiwei Han, Ling Hao, Haifei Chen and Yi Wang and has published in prestigious journals such as International Journal of Molecular Sciences, Molecular Pharmacology and European Journal of Pharmacology.

In The Last Decade

Yongli Du

29 papers receiving 388 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yongli Du China 14 247 58 57 55 47 29 394
Kateryna Kondratska France 11 333 1.3× 75 1.3× 64 1.1× 45 0.8× 23 0.5× 12 622
Hayoung Hwang South Korea 13 210 0.9× 52 0.9× 46 0.8× 87 1.6× 50 1.1× 28 423
Michael K. Manion United States 12 397 1.6× 74 1.3× 35 0.6× 57 1.0× 20 0.4× 14 529
Ewa Totoń Poland 15 356 1.4× 63 1.1× 33 0.6× 41 0.7× 17 0.4× 38 558
Andrey V. Markov Russia 12 231 0.9× 43 0.7× 46 0.8× 54 1.0× 19 0.4× 41 392
Abdullah A. A. Alghamdi Saudi Arabia 12 183 0.7× 61 1.1× 50 0.9× 36 0.7× 12 0.3× 35 423
Subhankar Biswas India 12 497 2.0× 77 1.3× 69 1.2× 34 0.6× 45 1.0× 22 713
Xiaoqian Xue China 12 391 1.6× 95 1.6× 70 1.2× 59 1.1× 59 1.3× 16 686
Tzu-Chun Cheng Taiwan 12 438 1.8× 129 2.2× 48 0.8× 58 1.1× 26 0.6× 16 615
Natalia Lisiak Poland 13 282 1.1× 50 0.9× 32 0.6× 40 0.7× 22 0.5× 31 446

Countries citing papers authored by Yongli Du

Since Specialization
Citations

This map shows the geographic impact of Yongli Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongli Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongli Du more than expected).

Fields of papers citing papers by Yongli Du

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongli Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongli Du. The network helps show where Yongli Du may publish in the future.

Co-authorship network of co-authors of Yongli Du

This figure shows the co-authorship network connecting the top 25 collaborators of Yongli Du. A scholar is included among the top collaborators of Yongli Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongli Du. Yongli Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Tianxiao, Rui Li, Yongli Du, et al.. (2021). The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer in vivo. Journal of Enzyme Inhibition and Medicinal Chemistry. 37(1). 125–134. 5 indexed citations
2.
Du, Yongli, et al.. (2021). Molecular Modeling Studies of [4-(3 H -benzoimidazol-5-yl)-pyrimidin-2-yl]-amine-based CDK4 Inhibitors. Future Medicinal Chemistry. 13(16). 1317–1339. 1 indexed citations
3.
Reddy, Karnati Konda, Yixuan Wang, & Yongli Du. (2020). Exploring the binding mode and thermodynamics of inverse agonists against estrogen-related receptor alpha. RSC Advances. 10(28). 16659–16668. 4 indexed citations
4.
Zhang, Yanhui & Yongli Du. (2018). The Development of Protein Tyrosine phosphatase1B Inhibitors Defined by Binding Sites in Crystalline Complexes. Future Medicinal Chemistry. 10(19). 2345–2367. 9 indexed citations
5.
Zhang, Liudi, Jie Shao, Haifei Chen, et al.. (2018). Inhibition of PDGF-BB-induced proliferation and migration in VSMCs by proanthocyanidin A2: Involvement of KDR and Jak-2/STAT-3/cPLA2 signaling pathways. Biomedicine & Pharmacotherapy. 98. 847–855. 31 indexed citations
6.
Li, Rui, et al.. (2018). Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR. International Journal of Molecular Sciences. 19(4). 1244–1244. 7 indexed citations
7.
Du, Yongli, et al.. (2017). Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies. Anti-Cancer Agents in Medicinal Chemistry. 17(5). 646–657. 3 indexed citations
8.
Han, Weiwei & Yongli Du. (2017). Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors. Chemistry & Biodiversity. 14(7). 19 indexed citations
9.
Du, Yongli, Liudi Zhang, Ling Hao, et al.. (2017). The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer. European Journal of Medicinal Chemistry. 136. 457–467. 24 indexed citations
10.
Yang, Ning, Haifei Chen, Yongli Du, et al.. (2017). A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α. Biomedicine & Pharmacotherapy. 93. 913–922. 7 indexed citations
11.
Du, Yongli, Yanhui Zhang, Ling Hao, Qunyi Li, & Jingkang Shen. (2017). Discovery of novel high potent and cellular active ADC type PTP1B inhibitors with selectivity over TC-PTP via modification interacting with C site. European Journal of Medicinal Chemistry. 144. 692–700. 16 indexed citations
12.
Li, Qunyi, Yi Wang, Liudi Zhang, et al.. (2016). Naringenin exerts anti-angiogenic effects in human endothelial cells: Involvement of ERRα/VEGF/KDR signaling pathway. Fitoterapia. 111. 78–86. 51 indexed citations
13.
Zhang, Liudi, Peihong Liu, Haifei Chen, et al.. (2016). Characterization of a selective inverse agonist for estrogen related receptor α as a potential agent for breast cancer. European Journal of Pharmacology. 789. 439–448. 16 indexed citations
14.
Liu, Peihong, et al.. (2016). Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity. European Journal of Medicinal Chemistry. 118. 27–33. 23 indexed citations
15.
Li, Qunyi, Yingfeng Zhu, Meng Zhang, et al.. (2015). Chlorogenic acid inhibits hypoxia-induced pulmonary artery smooth muscle cells proliferation via c-Src and Shc/Grb2/ERK2 signaling pathway. European Journal of Pharmacology. 751. 81–88. 27 indexed citations
16.
Du, Yongli, Ling Hao, Meng Zhang, Jingkang Shen, & Qunyi Li. (2015). Discovery of novel, potent, selective and cellular active ADC type PTP1B inhibitors via fragment-docking-oriented de novel design. Bioorganic & Medicinal Chemistry. 23(15). 4891–4898. 18 indexed citations
17.
Liu, Peihong, et al.. (2015). Novel, potent, selective and cellular active ABC type PTP1B inhibitors containing (methanesulfonyl-phenyl-amino)-acetic acid methyl ester phosphotyrosine mimetic. Bioorganic & Medicinal Chemistry. 23(21). 7079–7088. 18 indexed citations
18.
Wang, Yancai, Yi Ma, Yingying Ma, et al.. (2012). Formulation and Pharmacokinetics Evaluation of Puerarin Nanocrystals for Intravenous Delivery. Journal of Nanoscience and Nanotechnology. 12(8). 6176–6184. 21 indexed citations
19.
20.
Du, Yongli, Qunyi Li, Bing Xiong, et al.. (2010). Aromatic β-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists. Bioorganic & Medicinal Chemistry. 18(12). 4255–4268. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kateryna Kondratska Breakdown of academic impact, for papers by Hayoung Hwang Breakdown of academic impact, for papers by Michael K. Manion Breakdown of academic impact, for papers by Ewa Totoń Breakdown of academic impact, for papers by Andrey V. Markov Breakdown of academic impact, for papers by Abdullah A. A. Alghamdi Breakdown of academic impact, for papers by Subhankar Biswas Breakdown of academic impact, for papers by Xiaoqian Xue Breakdown of academic impact, for papers by Tzu-Chun Cheng Breakdown of academic impact, for papers by Natalia Lisiak
Rankless by CCL
2026